← Leaderboards
Vidya P Ramamurthy
Isoprene Pharmaceuticals, Inc.
$1,506,361
Attributed
$3,012,722
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2021–25$2M$1.5M$1M$500K$0
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,012,722 · 2
By mechanism
R44$3,012,722 · 2
Top collaborators
- Vincent Collins Ofuka Njar3 shared
Others in their field
Other Emerging Leaders on “First-In-Human”
- Yunda Huang · Fred Hutchinson Cancer Center$52,003,716
- Xinhua Li · Nano Terra, Inc.$29,991,620
- Kathleen Maletic Neuzil · Emory University$27,466,472
- Sonia Minikel Vallabh · Broad Institute, Inc.$15,007,691
- Jeffrey Reich · Sparian Biosciences, Inc.$14,845,721
- Richard Scranton · Lyndra Therapeutics, Inc.$12,106,230
Research focus
First-In-HumanFormulationCytokineFeasibility TestingDrug KineticsDoseAwardAnimalsCommercializationExhibitsBiological TestingApoptosisCancer RecurrenceAnalytical MethodCancer TypeCanis FamiliarisCardiovascular SystemCell Cycle RegulationAntineoplastic AgentsChemokineEffective TherapyEvaluationClinical TrialsFunding
Grant awards (3)
Development of VNPP433-3Beta as Novel Therapeutic for All Stages of Prostrate Cancer$1,022,522
R44 · FY2025 · CA · contact PI
Development of VNLG-152R as novel therapeutic for triple negative breast cancer$995,100
R44 · FY2022 · CA · contact PI
Development of VNLG-152R as novel therapeutic for triple negative breast cancer$995,100
R44 · FY2021 · CA · contact PI